UNSPSC 51402404: Prazitone hydrochloride

This classification denotes an antidepressant agent C16H19N3O3.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1N7P630564, chemically known as barbituric acid, 5-phenyl-5-(2-piperidylmethyl)-, monohydrochloride, but more generally known as prazitone hydrochloride, which bears US NIH Compound Identifier 24845095. European Medicines Agency schedules Prazitone hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04012MIG.

Most nations, for tariff and trade purposes, schedule prazitone hydrochloride under HS 29335400 and SITC kg. As of Q4 2014, PRAZITONE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. SMILES: C1CCC(CC1)C2(C(=O)NC(=O)NC2=O)CC3CCCCN3.CL.

UNSPSC 51402404 Prazitone hydrochloride is a Commodity code that in practice covers pharmaceutical products procured by state and local health agencies, though the recent opportunities in the dataset show minimal direct activity under this specific code. The three most recent state and local opportunities tagged to pharmaceutical procurement involve naloxone and drug deactivation systems, direct-to-manufacturer prescription programs, and multi-source generic pharmaceuticals and OTC products, none of which are prazitone-specific. The issuing bodies include county health departments (Seminole County, Florida), state health and human services commissions (Texas HHS), and multi-state cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance, or MMCAP, serving Minnesota, Oregon, and other participating jurisdictions). Work solicited under related pharmaceutical codes spans both procurement of finished pharmaceutical products for direct health service delivery and the establishment of supplier relationships for ongoing statewide or multi-jurisdictional pharmacy benefit programs.

Geographic activity is concentrated in the South and Upper Midwest, with recent opportunities from Florida, Texas, and Minnesota. The most mature opportunity is Seminole County's IFB60459723LAS, issued June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with a July 26, 2023 response deadline and a two-year initial term with one-year renewal option; delivery is quarterly to the Seminole County Community Health Building in Sanford, Florida, with all shipping included in bids. The Texas HHS Commission issued an RFI on April 3, 2026 to gather market intelligence on direct-to-manufacturer pharmacy programs, designed to inform future formal solicitations. MMCAP's RFP for generic multi-source pharmaceuticals and OTC products, posted January 20, 2026 with a March 26, 2026 deadline, targets manufacturers supplying through three authorized wholesalers with awards effective July 1, 2026 and a two-year contract term. The code itself shows limited standalone recent activity; opportunities tagged under pharmaceutical procurement cluster around supply programs and benefit management rather than prazitone as a discrete product line.